Researchers identified MPOL_B_1, a novel geroprotector compound that extends C. elegans lifespan by up to 30% through virtual screening targeting the proton-coupled folate transporter (PCFT). The compound demonstrated drug-like properties in vitro and showed a favorable safety profile in both mice and rats, suggesting good translational potential. This discovery represents a meaningful addition to the limited arsenal of validated longevity compounds. Targeting folate transport pathways for lifespan extension is particularly intriguing because folate metabolism intersects with critical aging mechanisms including DNA synthesis, methylation reactions, and mitochondrial function. The 30% lifespan extension places MPOL_B_1 among the more potent geroprotectors tested in C. elegans, comparable to effects seen with rapamycin or metformin. However, significant limitations remain: the mechanism of action is unclear, effects are demonstrated only in a simple model organism, and the compound requires extensive human safety testing. While promising, this represents early-stage drug discovery rather than a near-term therapeutic breakthrough. The work does validate PCFT as a novel longevity target worth pursuing in mammalian studies.